stockrowCogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Free cash flow
Cogent Biosciences, Inc.'s free cash flow for fiscal 2025 was −$266.0M, compared with −$208.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$309.2M. Over the past ten years it has ranged from −$266.0M (fiscal 2025) to $15.7M (fiscal 2015) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Cogent Biosciences, Inc. ranks 568th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$266.0M | — |
| FY2024 | −$208.4M | — |
| FY2023 | −$156.4M | — |
| FY2022 | −$125.5M | — |
| FY2021 | −$60.5M | — |
| FY2020 | −$27.4M | — |
| FY2019 | −$41.3M | — |
| FY2018 | −$33.0M | — |
| FY2017 | −$26.7M | — |
| FY2016 | −$21.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$77.6M | — |
| Mar 2026 | −$87.3M | — |
| Dec 2025 | −$79.9M | — |
| Sep 2025 | −$64.4M | — |
| 36 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $85.3M |
| MANE Veradermics Incorporated compare | −$123.0M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.9M |
| ERAS Erasca, Inc. compare | −$252.1M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| SRRK Scholar Rock Holding Corporation compare | −$297.0M |
| COGT Cogent Biosciences, Inc. | −$309.2M |
| CRSP CRISPR Therapeutics AG compare | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement